FDA accepts Jazz cannabidiol capsule application and sets April decision date

FDA accepted Jazz Pharmaceuticals' application for cannabidiol capsules and set an April 16, 2027 target decision date. The filing highlights a regulated cannabinoid-drug channel that is distinct from dispensary products, reinforcing the need for Oklahoma operators to avoid unapproved medical claims while monitoring pharmaceutical competition.